title: Molecular surgery for the treatment of malignant tumors: bioincompatible material apheresis for cancer therapy?
abstract: Controlled immunological shock, induced by bioincompatible material apheresis for cancer (BIC MAC) therapy, produces an immunoactive status in experimental subjects. However, in order to provide a safe, painless, effective, and reproducible BIC MAC therapy, it is mandatory to provide general anesthesia with endotracheal intubation not only during apheresis procedures of 1-h duration but also for an additional 5 h. Using this procedure, there was no mortality experienced during animal experiments. Also, there were no procedurally related physical or sensory abnormalities demonstrated. This general anesthesia of 6 h covered not only the initial 30 min of the hypotension and hypoxic stages but also the recovery stages to hemodynamically normalize the experimental animals. After 6 h, the accumulated leukocytes in the lung are released back to the systemic circulation. In general, granulocytes decreased almost 100% while lymphocytes decreased only 40-50%. During these 6 h, increases of cytokines (tumor necrosis factor-α, interleukin-6, etc.) sometimes up to 1000 times occurred. After the 6-h procedure, leukocytes returned nearly to preoperative levels but tended to be continuously increased. After the fourth day, leukocyte counts more than doubled. These cellular and humoral activations were normalized after 2 weeks. These studies were conducted on six normal mongrel dogs. Currently, similar studies are planned to be conducted on tumor-bearing experimental animals. This procedurally induced immunoactivation by apheresis may be able to produce effective apoptosis in malignant tumor cells.
authors.affiliation: Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. ynose@bcm.tmc.edu
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Nosé
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Ohta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Junji
authors.initials: J
authors.lastname: Takaba
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Natsume
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000627:therapeutic use*; D001781:Blood Component Removal / Q000295:instrumentation* / Q000379:methods; D016207:Cytokines / Q000276:immunology; D004285:Dogs; D007167:Immunotherapy / Q000295:instrumentation* / Q000379:methods; D047589:Leukocyte Reduction Procedures / Q000295:instrumentation* / Q000379:methods; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D001672:Biocompatible Materials; D016207:Cytokines